Subscribe To
Clearside Biomedical Announces First Quarter 2023 Financial Results and Provides Corporate Update
– Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Expected to Open Enrollment in Q2 2023 – – Positive Safety Data, Duration and Biologic Effect of CLS-AX Over 6 Months in OASIS Phase 1/2a Extension Study Highlighted in Presentations at Recent Medical Meetings – – Management to Host Webcast and Conference Call Today at […] The post Clearside Biomedical Announces First Quarter 2023 Financial Results and Provides Corporate Update appeared first on ForexTV...
Read More
Posted: May 11 2023, 11:05
Author Name: forextv
Views: 111039